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A novel high affinity dopaminergic ligand, N-(p-aminophenethyl)spiraperidol, has been synthesized and ra- 
dioiodinated to a specific radioactivity of 2175 Ci/mmol. Binding of this ligand to bovine anterior pituitary 
membranes is: (if rapid (40-60 min to equilibrium at 25°C) and reversible (‘f,z = 1 h at 25°C); (ii) saturable 
and of high affinity (KD - 20 pM) and (iii) displays a typical D,-dopaminergrc specificity. The ligand, which 
identities the same number of receptor sites as other tritiated antagonist ligands, can be used in different 
tissues and preparations to delineate the characteristics of the D, receptor. Thus, this high affinity, high 
specific radioactivity ligand (N-~-amino-~-[12sI]iodophenethyl~spiro~~dol) represents a tool which until 
now had not been available for the ch~a~te~~tion of the D,-dopamine receptor. 
Didopamine receptor Radioiodinated ligand 
1. INTRODUCTION 
Radiolig~ds have been very powerful tools in 
studies aimed at elucidating the biochemical events 
by which hormones and neurotransmitters mediate 
their physiological effects as well as the molecular 
mechanisms by which responsiveness can be modu- 
lated. Thus, the ability to measure hormone and 
neurotransmitter receptors has revealed that recep- 
tors are points of dynamic regulation in target 
tissues [I]. However, the feasibility of such studies 
often depends on the availability of appropriate 
tools for the detection of low concentrations of 
these receptors in target tissues. The specific recep- 
tors which mediate the various physiology actions 
of dopamine in central and peripheral target tis- 
sues have been characterized extensively by direct 
ligand binding. These receptors have been classi- 
fied into two distinct subtypes designated Dr- and 
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Dz-dopamine receptors [2]. For the Dz-dopamine 
receptor, although the initial tritiated ligands were 
developed about a decade ago [3,4] there has been 
to data no high affinity, high specific radioactivity 
ligand available for receptor identification. The 
antagonist, [3H]spiroperidol {S] and the agonist 
[3H](-)~-propylnora~mo~hine [6], two of the 
more widely used ligands, bind to the Ds-dopa- 
mine receptor with high affinity (& - 50-300 PM) 
[7]. However, their modest specific radioactivity 
(2~~Ci/rnrnol~ often limits their versatility as 
ligands .
We describe the properties of a new ligand, an 
analog of the antagonist spiroperidol, which can 
be radioiodinated to theoretical specific activity 
(2175 Ci/mmol) and which binds to the Dz-dopa- 
mine receptor with very high affinity (KD - 20 PM). 
The properties of this ligand offer distinct advan- 
tages for the measurement of the Dz-dopamine 
receptor and its eventual biochemical characteriza- 
tion. 
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2. MATERIALS AND METHODS 
Materials used in these studies (drugs and radio- 
ligands) were from sources previously described 
[7]. Na”‘I was obtained from New England 
Nuclear, Boston, MA, whereas chemicals were 
usually from Aldrich, Milwaukee, WI. 
2.1. Synthesis and radioiodination of the iigand 
The chemical synthesis and characterization of 
the newly developed compound N-(p-aminophene- 
thyl)spiroperidol (NAPS) will be detailed elsewhere 
[ 121. The radioiodination of NAPS was performed 
essentially as described previously [8] for the fi- 
adrenergic antagonistp-aminobenzylcarazolol. The 
iodinated ligand was separated from the non- 
radioactive ligand by thin-layer chromatography in 
the solvent system methylene chloride : metha- 
nol : triethylamine (87.5 : 12.5 :0.01) RfwAPs) :0.5; 
Rf(1~2~rl~Aps) : 0.65. The [iz51]NAPS was eluted from 
the plate with ethyl acetate containing 1% triethyl- 
amine and stored at - 1 mCi/ml in ethanol, 0.01% 
phenol or isopropanol : water (50 : 50) for several 
weeks without chemical damage. Since carrier-free 
Nai2’I was used for the radioiodination and 
[‘251]NAPS could be completely separated from 
unlabelled NAPS a specific radioactivity of 
2175 Ci/mmol could be assumed for [ 1251]NAPS. 
2.2. Anterior pituitary membranes 
Bovine anterior pituitary membranes were pre- 
pared essentially as in [7], resuspended in 25 mM 
Tris-HCl, pH 7.4 (25’C), 6mM MgClz, 1 mM 
EDTA and stored frozen at -7O’C until used. 
2.3. Radioligand and binding assays 
Assays were performed by incubating 100~1 of 
membranes containing 300-8OOpg protein/ml (for 
[‘251]NAPS binding) with the appropriate ligand 
and competitors in a total volume of 1 ml of the 
resuspension buffer containing 0.1% ascorbate. 
After incubation for 1 h (or the indicated time) at 
25°C bound ligand was separated from free ligand 
by filtration through GFK glass fiber filters and 
washing the filters with 4 x 5 ml of 50 mM Tris- 
HCI, pH 7.5 (25”C), 0.1% BSA, 0.01% Triton 
X-100. [3H]Spiroperidol binding was determined 
as previously described 171. Bound ligand was 
determined by liquid scintillation (45% efficiency) 
or by counting in a gamma counter (75% effi- 
ciency). Bovine serum albumin and Triton X-108 
were included in the wash buffer in order to reduce 
the level of nonspecific binding, contributed in 
large part by the interaction of the ligand with the 
glass fiber filter matrix. 
Analysis of binding data was performed as in 
[7]. Protein determinations were performed by the 
method of [9]. 
3. RESULTS AND DISCUSSION 
3.1. Kinetics and optimal conditions for 
[“‘IJNAPS binding 
At 25°C [1251]NAPS binding to bovine anterior 
pituitary membranes reached equilibrium between 
40 and 60 min of incubation (fig.1). Binding was 
completely reversible upon the addition of excess 
(+)-butaclamol (1 CM) with a half-time of -60 min. 
The ratio of the dissociation to the association rate 
constants yielded an estimated dissociation con- 
stant (KD) value for the binding of [“‘I]NAPS to 
these membranes of 6-10 pM (n = 2). The binding 
of [r2’I]NAPS to anterior pituitary membranes 
was found to be linear over at least a 20-fold range 
of protein in the assay (5-1OOpg). 
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Fig.1. Kinetics of the binding of [1251]NAPS to bovine 
anterior pituitary membranes. Membranes were incu- 
bated at 25°C as described in section 2 in the presence 
(0) and absence (0) of l#M (+)-butaclamol with 
30-40 pM [ ‘*‘I]NAPS. At the indicated times, samples 
were filtered through OF/C glass fiber filters to deter- 
mine bound ligand. Dissociation was initiated by the 
addition of 1 pM (+)-butaclamol to incubation mixtures 
after an equilibration time of 90min. The dissociation 
constant (KD) of [1251]NAPS from the ratio of the rate 
of dissociation and association was calculated according 
to [lo]. Results are from 3 experiments. 
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[[1251] NAPS] pM 
Fig.2. Saturation binding isotherms for [‘251]NAPS. An- 
terior pituitary membranes (62pg) were incubated as 
described in section 2 with increasing concentrations of 
I’*‘IlNAPS in the presence (0) and absence (0) of 1 /rM 
(+)-butackunol. Incubations were carried out at 25~ 
for 3 h to insure equilibrium binding of the lower ligand 
concentrations. Total ligand concentrations were deter- 
mined by sampling each incubation mixture at the end of 
the incubation period before separation of bound from 
free ligand. Results are from 3 experiments. 
3.2. Equilibrium binding of [12sI/NAPS 
Binding of [‘251]NAPS to bovine anterior pitui- 
tary membranes was saturable, as shown in fig.2. 
From the data shown, a KD value of 17.1 pM 
(19.5 f 2.3, n = 3) could be estimated, which is 
over an order of magnitude more potent than the 
reported KD value for [3H]spiroperidol in this 
tissue (0.3 nM) [l 11. Specific binding ranged from 
80-85% of total binding at low ligand concentra- 
tions to 50-60070 at high ligand concentrations. In 
the experiment shown a BmaX of 6.7 pM was deter- 
mined for the number of sites occupied at satura- 
tion. This value corresponds to a concentration of 
binding sites of 52 fmol/mg and is in reasonable 
agreement with an estimate of 60 fmol/mg ob- 
tained using [3H]spiroperidol as the ligand in the 
same membrane preparation. 
3.3. Specificity of the binding of [“‘IjNAPS 
As shown in fig.3, the ability of a variety of 
agonists (A) and antagonists (B) to compete for the 
binding of [ ‘*‘I]NAPS to bovine anterior pituitary 
was typical of a Dzdopaminergic binding site. The 
typical order of potency NPA > ADTN 2 APO > 
DA was observed for agonists. For antagonists, 
spiroperidol, unlabelled NAPS and (+)-butaclamol 
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Fig.3. Competition curves of a series of dopaminergic 
agonists (A) and antagonists (B) for the binding of 
[ ‘2sI]NAPS to bovine anterior pituitary membranes. 
Membranes were incubated with -40 pM [ 12’I]NAPS in 
the presence of increasing concentrations of the various 
agonists (A) and antagonists(B) shown. NPA, (-)-N-pro- 
pylnorapomorphine; (+)-ADTN, (+)-2-amino6,7dihyd- 
roxytetrahydronaphthalene; APO, (-)-apomorphine; 
DA, dopamine. Binding is expressed in (70 of specific 
binding and 100% control corresponds to 4.8-6.5 pM 
[1251]NAPS bound. Results are from 3-5 experiments. 
were about equipotent whereas (-)-butaclamol was 
-10000 fold less potent than the (+) isomer of 
butaclamol. The estimated KD values of these and 
other dopaminergic and non-dopaminergic drugs 
are shown in table 1. The calculated KD values for 
these drugs are in good agreement with those ob- 
tained using [3H]spiroperidol as the radioligand 
[7,11]. Note that for agonists the competition 
curves are shallow and model to two affinity sites, 
thus KD values for the high and low agonist affinity 
states of the receptor have been compiled. As shown 
earlier using [ 3H]spiroperidol [7,11], these biphasic 
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Table 1 
Dissociation constants bf dopaminergic and non-dopa- 
minergic agents 
Agents Dissociation constants 
KD (nM) 
KH KL 
Agonists 
(-)-iV-Propylnorapomorphine 0.43 15.8 
(k)-ADTN 1.07 66.5 
(-)-Apomorphine 13.4 338 
Dopamine 67.2 9320 
Antagonists 
(+)-Butaclamol 
(-)-Butaclamol 
Spiroperidol 
NAPS 
(-)-Sulpiride 
0.36 
2620 
0.25 
0.33 
608 
Nondopaminergic antagonists 
Phentolamine 
Mianserin 
Cinanserin 
Prazosin 
Propranolol 
9400 
6200 
7200 
5350 
>lOOOO 
Dissociation constants (KD) were estimated by quantita- 
tive analysis [7] from 8-12 points competition curves of 
the various agents hown for the binding of [“‘I]NAPS 
to bovine anterior piruitary membranes. For agonists the 
curves were better fit to a two-affinity state model [7] 
and therefore both KH and KL are shown. The results 
represent he geometric average of 2-3 experiments 
performed in duplicate 
agonist competition curves can be steepened and 
shifted to the right in the presence of guanine 
nucleotides. For example, in the presence of 
lOO/cM Gpp(NH)p the competition curve of NPA 
for [12sI]NAPS binding displays a single affinity 
state, the KD value of which corresponds to the 
value for the low affinity form of the receptor in 
the control curve (15-20 nM; cf., table 1) (not 
shown). 
These findings are in excellent agreement with 
previous studies using [3H]spiroperidol as the 
radioligand. Moreover, [r2?]NAPS has also been 
used in preparations uch as rat striatal membranes 
and solubilized preparations of anterior pituitary 
membranes to monitor effectively Dz-dopamine 
receptors (not shown). 
In summary, this newly developed ligand, 
[ ‘251JNAPS, possesses high affinity (KD - 20 PM) 
for binding to the Dz-dopamine receptor. It binds 
to membrane preparations containing dopamine 
receptors with an appropriate D2-dopaminergic 
specificity. In binding assays it yields a high ratio 
of specific to nonspecific binding. The ligand can 
be used in all preparations of Dz receptors so far 
tested with higher affinity than [3H)spiroperidol. 
However, the cardinal property of [‘251]NAPS is 
its high specific radioactivity (2175 Ci/mmol), 
which allows a SO-lOO-fold more sensitive detec- 
tion of Dz receptors than conventional ow specific 
radioactivity [3H]ligands. Therefore, this probe 
should be extremely useful in attempts at charac- 
terizing the receptor at the biochemical evel. 
The strategy employed in the development of 
this ligand was aimed at yielding a multifunctional 
probe for the D2-dopamine receptor. The presence 
of an arylamine moiety on the molecule not only 
allows radioiodination of the ligand but this aryla- 
mine moiety can be easily converted to an azide [8] 
to yield a specific iodinated photoaffinity probe 
for the receptor. Moreover, the a&mine group 
can be easily derivatized for the purpose of affinity 
chromatography. Thus, these various applications 
should make this compound one of the most useful 
probes yet available for the characterization of the 
Dz-dopamine receptor. 
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